Explore Medicare coverage limitations for Saxenda, a GLP-1 agonist approved for weight loss, and the implications for obesity drug access and insurance plan strategies.

CMS's price-substitution policy has saved $76 million for Medicare by correcting drug pricing identified by the Office of Inspector General, improving cost efficiency while maintaining access.

CMS initiates survey collecting hospital outpatient drug acquisition costs to align Medicare payments with actual costs under the 2026 OPPS update, following a federal Executive Order to reduce prescription drug expenses.

Pennsylvania Senate passes Bill 95 with amendment requiring pharmacies to disclose retail and generic drug prices upon consumer request, promoting prescription drug cost transparency and informed purchasing decisions.

Explore the Medicare Part D coverage gap's impact on U.S. retirees, with insights on managing prescription drug costs and navigating supplemental insurance options.

U.S. federal agencies issue new guidance and requests for information to improve transparency in prescription drug and hospital prices, aiming to enhance data accuracy and compliance.

Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.

Explore how Medicare Part D and C plans cover Jardiance for heart failure and type 2 diabetes, including costs, formularies, and pricing reforms under the Inflation Reduction Act.

Explore how Medicare covers diabetes treatments and costs including Metformin and other diabetic supplies under Parts A, B, C, and D. Understand cost factors like premiums and deductibles.

President Trump signs an executive order to lower U.S. prescription drug prices, amending key Medicare negotiations. Learn how this could impact the healthcare and insurance sectors.